Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial

SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis

“…And in some cases, the use of antiviral drugs early during the viral infection in patients with AIIDs is a must, although they have been vaccinated (i.e., in case of influenza). For other cases, the increased dosage of influenza vaccine would help counteract the reduced response; or to pause the treatment temporarily or just before the vaccine is administered and resuming after two weeks for patients on methotrexate who are at high risk for influenza [ 35 ].…”

A vaccination update for rheumatologists—SARS‐CoV‐2, influenza and herpes zoster

“…A Canadian study randomized 279 patients with RA to standard‐dose quadrivalent influenza vaccine (SD‐QIV) and 139 to a high‐dose trivalent preparation (HD‐TIV). Those who received HD‐TIV were more likely to seroconvert than those who received SD‐QIV with OR of 2.99 (95% CI 1.46‐6.11) for seroconversion to strain A/H3N2, 1.95 (1.19‐3.22) for strain B/Bris, 3.21 (1.57‐6.56) for strain A/H1N1 (in 2016‐2017), and 2.44 (1.18‐5.06) for seroconversion to strain A/H1N1 (in 2017‐2018) 25 . No flare in RA activity was observed following either vaccine.…”

“…All immunosuppressed AIIRD patients who receive the seasonal influenza vaccine for the first time should receive 2 vaccine doses, at least 4 weeks apart, and 1 dose annually thereafter on an ongoing basis 31,32 . Consideration should be given to vaccinating immunosuppressed AIIRD patients with an adjuvant or high‐dose seasonal influenza vaccine – if available 25 …”

Immunogenität und Sicherheit von Hochdosis vs. Standarddosis eines inaktivierten Influenzaimpfstoffes bei Patienten mit rheumatoider Arthritis

“…Eine Möglichkeit zur Optimierung der Impfantwort besteht in der Erhöhung der Impfstoffdosis, was im Falle der Influenzaimpfung für über 65-jährige Patienten nachgewiesen wurde [3]. Die Autoren der hier vorgestellten kanadischen Arbeit haben untersucht, ob RA-Patienten von einem höher dosierten Impfstoff gegen Influenza profitieren [4]. Dafür verabreichten sie in einer randomisierten doppelblinden Studie seropositiven RA-Patienten den von der Firma Sanofi Pasteur entwickelten trivalenten Impfstoff mit 65 μg Hämagglutinin (HD-TIV) vs. den quadrivalenten Impfstoff in der Standarddosierung mit 15 μg Hämagglutinin (SD-QIV) […”